<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573456</url>
  </required_header>
  <id_info>
    <org_study_id>GAAD-DM-CTP1</org_study_id>
    <nct_id>NCT00573456</nct_id>
  </id_info>
  <brief_title>Far Infrared Radiation Treatment for Diabetes</brief_title>
  <official_title>Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GAAD Medical Research Institute Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GAAD Medical Research Institute Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine the use of far infrared (FIR) radiation for treatment of diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus is a disease in which glucose is not sufficiently metabolized. This results
      in high glucose levels in blood and glucose in the urine. Cells can starve because glucose is
      not being metabolized.

      Both types of diabetes can cause dangerous complications, including blindness, heart and
      blood vessel disease, and kidney failure. A decrease in circulation may eventually require
      the amputation of limbs.

      We are postulating that energy specific electromagnetic radiation of the central nervous
      system, the viscera and the endocrine system has the potential to enhance the immune system;
      thereby improving the health of the patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Far Infrared Radiation</intervention_name>
    <description>Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons with type 1 or type 2 diabetes

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Nedd, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>GAAD Medical Research Institute Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwasi Donyina, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>GAAD Medical Research Institute Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Centre for Incurable Diseases</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <last_update_submitted>August 14, 2009</last_update_submitted>
  <last_update_submitted_qc>August 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Kwasi Donyina/Founder &amp; President</name_title>
    <organization>GAAD Medical Research Institute Inc.</organization>
  </responsible_party>
  <keyword>Thye 1 Diabetes</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

